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Abstract Dupuytren’s contracture is a benign fibromatosis of
the palmar and digital fascia of the hand of uncertain etiology,
resulting in nodules and cords beneath the skin of the palm of
the hands that may lead to the development of contractures.
Surgical in tervent ion is of ten considered when
metacarpophalangeal (MP) joint contracture is 30° or more,
or when there is any degree of proximal interphalangeal (PIP)
joint contracture. Collagenase clostridium histolyticum
(CCH) is a nonsurgical, minimally invasive enzymatic drug
indicated for the treatment of adult patients with Dupuytren’s
contracture (DC) and palpable cord. CCH has been available
for approximately 3.5 years, and postapproval experience
indicates that the effectiveness of CCH is equivalent to or
better than efficacy observed in clinical trials, as seen by lower
injection rates to achieve clinical success. Postapproval expe-
rience has shown a risk-benefit profile that favors CCH for
patients not indicated for surgery based on current recommen-
dations and shows also that treating earlier-stage vs later-stage
joint contracture results in significantly better outcomes on
average. Postapproval surveillance reveals a safety profile
similar to that observed in clinical trials. Nonserious adverse
events are mainly local reactions; tendon rupture, a serious
adverse event, is reported rarely in the clinical practice setting
and at a lower rate than in clinical trials. Risk Evaluation and
Mitigation Strategy (REMS) training is designed to mitigate
benefit vs risk to achieve safe and effective use of CCH.
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Introduction
Dupuytren’s contracture (DC) is a connective tissue disorder
of the hand in which the development of tissue abnormalities
and subsequent contractures within the palmar fascia can
cause flexion deformity of the affected fingers, subsequently
limiting use of the hand. The disease may initially present as
f i rm nodu l e ( s ) i n t h e p a lm p r o x ima l t o t h e
metacarpophalangeal (MP) and proximal interphalangeal
(PIP) joints and then can progress to form cords [44].
Additionally, nodules, skin pitting, dimpling, tenderness, and
contracture of the MP or PIP joints may be present upon
examination [17, 30, 44, 47]. Typically, the disease progresses
slowly, and patients may put off consulting their physician
until the degree of disability keeps them from performing
work or recreational activities that require manual dexterity
of the affected hand; Dupuytren’s contracture can also limit a
patient’s ability to perform activities of daily living [47].
Epidemiology
Dupuytren’s disease (DD) is thought to mainly affect older
persons of northern European descent [44]. The prevalence of
DD varies with age, population groups surveyed (e.g., geo-
graphic location, age, patient characteristics), and methods of
data collection, with estimated prevalence rates ranging wide-
ly from 0.2% (in the general population) to as high as 56% (in
subgroups of patients with factors associated with DD) [22].
DiBenedetti estimated an incidence of 3 cases per 10,000
people in a large US population survey, consistent with an
earlier survey in a British population [17]. Bilateral disease
appears to be more common in men than women [34]. Men
S. M. Schulze (*)




Clinical Development, Auxilium Pharmaceuticals, 640 Lee Road,
Chesterbrook, PA 19087, USA
HAND (2014) 9:447–458
DOI 10.1007/s11552-014-9645-7
Postapproval clinical experience in the treatment
of Dupuytren’s contracture with collagenase clostridium
histolyticum (CCH): the first 1,000 days
typically present sooner than women, perhaps by as much as
10 years, and often present with more severe disease [47]. A
familial component is recognized, with a pattern of inheritance
suggesting an autosomal dominance with variable penetrance
[8, 25].
Treatment
Surgical intervention is usually considered when MP contrac-
ture is ≥30° or when there is any degree of PIP contracture [44,
47, 48]. The longer the deformity is allowed to progress, the
greater the chance of contracture becoming irreversible [47].
This is especially true of PIP contractures, and therefore, they
are often treated earlier and more aggressively. Historically,
partial, regional, or limited fasciectomy (excision of the con-
tracture) has been the most widely used surgical procedure
among hand surgeons because it is associated with a lower
rate of recurrence than fasciotomy (severing without excision)
[44]. Needle aponeurotomy is a minimally invasive technique
performed under local anesthesia and does not typically re-
quire formal postoperative hand therapy [5]. Although a com-
mon procedure in France, a US survey estimates about 12 %
of patients receive needle aponeurotomy [17, 42, 44].
Nonsurgical treatment in early DC can obviate surgical
risks [44]. Collagenase clostridium histolyticum (CCH) is a
minimally invasive, injectable enzymatic treatment approved
by the FDA in February 2010 for adult patients with DC and a
palpable cord [4]. CCH injected locally lyses and weakens the
collagen cord and leads to cord rupture, either spontaneously
or after a standardized finger extension/manipulation proce-
dure [4]. Advantages of this technique include no need for
hospitalization, surgery, or general or regional anesthesia;
prompt healing with generally localized adverse reactions;
low pain intensity of short duration; low risk of infection or
other wound healing complications; and little if any need for
traditional hand therapy [15, 21, 26, 31]. Since its introduc-
tion, utilization of CCH has grown from about 5 % of all
procedures for Dupuytren’s contracture in 2010 to about 30 %
in late 2013, which is generally correlated with a decrease in
percent of surgical procedures during the same period. This
procedure may be considered in patients who are not yet
candidates for surgical intervention or who are considering
surgical intervention but can potentially benefit from a less
invasive option.
The objective of this review is to provide practitioners with
a comprehensive update of current published and presented
data regarding the clinical efficacy and postapproval effective-
ness of CCH. In April 2013, we performed a PubMed search
using the search terms “Dupuytren” and “collagenase” to
identify key publications then refined the search to also iden-
tify relevant postapproval data. In addition, a search was
performed of abstracts/presentations from 2010–2013 annual
meetings of the American Society for Surgery of the Hand and
the American Association for Hand Surgery. The search
criteria included level 1–4 data, with particular emphasis on
efficacy, adverse events (AEs), recurrence, patient/physician
satisfaction, and cost-effectiveness.
Efficacy and safety of CCH in clinical trials
Experience with CCH is largely limited to clinical trial data.
Although these data provide limited information about the
effectiveness of CCH in the clinical practice setting, they
provide information about important considerations for prac-
tice, including durability of response, treatment of multi-cord
disease requiring multiple CCH procedures, as well as other
outcomes such as quality of life (QoL) and patient satisfaction
with treatment among patients who do not achieve reduction
to 0°–5° contracture.
Efficacy of CCH in pivotal clinical trials
The double-blind, placebo-controlled registration trials of
CCH (CORD I and CORD II) showed that CCHwas effective
and well tolerated in adult patients with a palpable cord and
MP contracture of 20°–100° or PIP contracture of 20°–80°
[21, 26, 53]. The primary endpoint was clinical success,
defined as reduction in primary MP or PIP joint contracture
to 0°–5° 30 days after the last injection. Patients received CCH
(0.58 mg per injection) administered at a maximum of three
injections per cord in the double-blind phase, separated by a
30-day interval between injections. At 24 h after injection,
patients returned to their treatment center for a standardized
passive finger extension procedure that applied moderate
pressure to achieve cord rupture (maximum 3 attempts) [26].
Both the injection technique and finger extension procedure
have been previously described [26]. Most of the patients
required one or two CCH injection procedures to achieve
clinical success in the primary joint treated [2]. The rates of
clinical success for the CCH and placebo in CORD I/II is
illustrated for all primary, primary MP, and primary PIP joints
in Fig. 1. In both trials, a greater percentage of patients treated
with CCH compared to placebo achieved clinical success [2].
Range of motion (ROM) is frequently used as an assess-
ment tool to evaluate the effect of surgical or other medical or
therapeutic interventions in the clinical setting [18]. Mean
ROM was significantly improved (P<0.001) for all primary
joints and primary MP joints in CORD I/II compared with
placebo but not for primary PIP joints in CORD II (ineligible
for analysis) (Fig. 2) [2]. A recent subanalysis of higher-risk
patients included in CORD I/II showed no difference in effi-
cacy or safety in CCH-treated patients by age, diabetes status,
or sex, with 63 % of the patients reaching the primary end-
point of clinical success [41].
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Results from two open-label clinical trials (JOINT I and
JOINT II) using the same treatment protocol as CORD I/II
have also been published [53]. Overall, clinical success was
achieved in 57 % (497/879) of MP and PIP joints, with an
average of 1.2 injections per cord; by joint type this was 70 %
(369/531) of MP joints and 37% (128/348) of PIP joints. Less
severely contracted MP and PIP joints (≤50° for MP and ≤40°
for PIP joints) responded better than more severely contracted
joints, which is consistent with the observation in the CORD I
trial where joints with less severe contractures were also more
likely to respond to treatment with CCH than were joints with
more severe contractures [21, 26, 53], indicating that treat-
ment when the contracture is less severe provides better out-
comes when using CCH. This is clearly illustrated in a
Fig. 1 Percent of patients with reduction in contracture to 5° or less in
overall primary, primary MP, and primary PIP joints after last injection in
CORD I/II. A primary joint was defined as the first joint selected for
injection; those treated second or third were considered nonprimary.
Selection of a primary joint was determined by the investigator. All joints
selected for injection had to meet the inclusion criteria for CORD I/II
trials. P values are based on Cochran-Mantel-Haenszel test vs placebo,
stratified by baseline severity and joint type. CCH collagenase clostridi-
um histolyticum, CORD collagenase option for reduction of Dupuytren’s
study,MPmetacarpophalangeal joint, PIP proximal interphalangeal joint
Fig. 2 Mean change (improvement) in ROM from baseline to after last
injection in overall primary, primaryMP, and primary PIP joints in CORD
I/II. A primary joint was defined as the first joint selected for injection;
those treated second or third were considered nonprimary. Selection of a
primary joint was determined by the investigator. All joints selected for
injection had to meet the inclusion criteria for CORD I/II trials. P values
are based on full factorial model analysis of variance (ANOVA) with
treatment group, joint type, and baseline severity as factors. CCH colla-
genase clostridium histolyticum, CORD collagenase option for reduction
of Dupuytren’s study, MP metacarpophalangeal joint, NA not applicable
due to ineligibility for statistical analysis, PIP proximal interphalangeal
joint
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combined analysis of randomized, double-blind phase 3 trials,
in which final degree of joint contracture was less for MP and
PIP joints of less severe contracture than joints of high con-
tracture [2, 19] (Fig. 3).
Satisfaction with treatment
The CORD I/II pivotal data were examined to evaluate
patient- and physician-reported satisfaction with CCH injec-
tion and to assess the value of a minimally invasive, nonsur-
gical intervention for DC [39]. Prior to treatment, patients
were asked to rate the severity of DC on a 4-point scale: none,
mild, moderate, and severe. At the end of the 90-day, double-
blind period, patients rated their satisfaction with treatment
using a 5-point Likert scale (very satisfied, quite satisfied,
neither satisfied nor dissatisfied, quite dissatisfied, very dis-
satisfied) and improvement in contracture using a 100-point
visual analog scale. Physicians independently rated initial
contracture severity using a 4-point scale and change in con-
tracture at the end of the double-blind period using a 7-point
Likert scale.
Data from 347 patients (249 CCH, 125 placebo) were
included in the analysis. Patient-rated improvement and pa-
tient satisfaction were significantly higher among CCH-
treated vs placebo-treated patients (P<0.001 for both) [39].
Physician-rated disease severity was significantly lower
(P<0.001) and change from baseline was significantly better
(P<0.001) at study end for CCH-treated vs placebo-treated
patients (Fig. 4). Notably, patient satisfaction ratings correlat-
ed with improved joint ROM after treatment (partial r=−0.29,
P<0.001 [controlling for treatment]). This correlation
between satisfaction and improvement in ROM suggests that
patient-rated satisfaction is related to improved ability to
perform activities of daily living (ADLs) as well as better
QoL, and therefore, improvement in ROM could represent a
meaningful criterion for determining the effectiveness of treat-
ment in a practice setting, which is not always clear solely
from clinical trial goniometric criteria.
Recurrence
Recurrence rates vary widely and are highly dependent on
various factors. Becker and Davis conducted a systematic
review of surgical interventions for primary DD [6]. The
study evaluated the literature supporting individual proce-
dures, focusing on data related to recurrence and complica-
tions to determine whether a particular technique appeared to
be more favorable than others. The systematic review found
major inconsistencies in reporting, with no agreed-upon
definition of recurrence as well as inconsistencies for
reporting the outcome of surgery, in that a variety of objec-
tive measurements were used to assess functional improve-
ment. There was also disparity in the recording of compli-
cations, with only 62 % of papers quoting rates for specific
complications. Werker et al. reported similar difficulties in
reporting of recurrence, noting that rates of recurrence varied
widely from 12 to 73 % for fasciectomy/aponeurectomy and
33 to 100 % for fasciotomy/aponeurotomy, mainly attributed
to differences in the definition of recurrence and the duration
of follow-up [52].
The Collagenase Option for Reduction of Dupuytren’s
Long-term Evaluation of Safety Study (CORDLESS) trial is
Fig. 3 Mean degree of
contracture and mean reduction in
contracture of MP and PIP joints
at baseline and after last injection
by primary joints and high or low
baseline severity. Individual cords
could receive up to three
injections; endpoint data are for
last injection. MP low severity,
≤50° contracture; MP high
severity, >50°; PIP low severity,
≤40°, PIP high severity, >40°.MP
metacarpophalangeal joint, PIP
proximal interphalangeal joint
450 HAND (2014) 9:447–458
currently evaluating recurrence after CCH in a 5-year follow-
up of patients initially treated in five previous clinical trials
(CORD I/II, CORD I extension, JOINT I/II). Results from
3 years of follow-up have so far been published [37]. In this
observational trial, recurrence was prospectively defined as
≥20° worsening of contracture in the presence of a palpable
cord or medical/surgical intervention to correct the new or
worsening contracture. Primary and secondary endpoints in-
cluded recurrence in patients who had achieved clinical suc-
cess (0°–5° contracture). Among the 643 patients treated in
the original studies, 1,080 joints (648 MP and 432 PIP) were
previously treated; among these 1,080 treated joints, 623
joints (58 %) had been successfully treated with CCH in the
previous trials. Recurrence was seen in 35 % (217/623) of
successfully treated joints. The study demonstrates that recur-
rence appears to occur with greater frequency in PIP joints
than MP joints. The 3-year recurrence rate was 56 % for PIP
joints and 27 % for MP joints that had achieved clinical
success, and the authors observed that the least durable re-
sponse occurred in high-severity PIP joints. Patients in
CORDLESS had been previously treated with CCH for a
maximum of eight injections per patient in the double-blind
and open-label extension, and no additional AEs or long-term
complications occurred as of the 3-year follow-up. There was
no systemic allergic reaction to CCH for patients retreated for
recurrence in CORDLESS.
Examination of mean contracture pattern over 3 years of
interim follow-up in CORDLESS patients showed that those
who had been successfully treated with CCH in the clinical
trials and were nonrecurrent maintained improvement in con-
tracture at a level similar to what had been achieved in clinical
trials for MP contracture or slightly higher for previously
treated PIP contracture [29]. The pattern of contracture
showed progression in recurrent patients slowly over 3 years,
but mean contracture still had not reached the pretreatment
degree of contracture by 3 years. Over the 3-year interval, only
7 % (43/623) of patients who had been successfully treated in
the trials had medical or surgical intervention [37].
Durability of response
The durability of response to CCH was evaluated by Curtin
et al. to identify factors that might predict durability [12].
Mean follow-up was 1,100 days from the first injection,
and 94 % of patients had a 3-year visit. This analysis was
based on the CORDLESS population consisting of 643
patients (1,079 joints). The predictors of durability for MP
joints were unilateral disease, a total contracture index
<110°, no prior surgical history for DC, and no family
history of DD. For PIP joint contracture, low baseline
severity was the only predictor of durable response, thereby
supporting early intervention. In addition, patients who
achieved full correction in the trials were less likely to
have recurrence (≥20° increase in contracture or medical/
surgical intervention) than those who had achieved partial
correction of contracture with CCH.
Earlier intervention
There are limited published data that show earlier intervention
(i.e., when contracture is less severe) produces better out-
comes. A retrospective chart review of 302 patients (61 earlier
stage, 241 later stage) having only one joint treated with CCH
in 2010 at 10 sites was conducted to determine if CCH treat-
ment in earlier-stage DC joint contracture (≤30° [MP or PIP
joints]) with a palpable cord resulted in a better contracture
outcomes than later-stage disease (>30° contracture) with a
palpable cord [49]. Final mean contracture angle was signifi-
cantly better in joints treated earlier rather than later (earlier,
3.8°±6.9°; later, 14°±18.0°; P<0.0001). Joints that were
Fig. 4 Patient satisfaction with
CCH compared with placebo.
P<0.001 CCH vs placebo for all
comparisons. CCH collagenase
clostridium histolyticum
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treated earlier showed an 85 % reduction in joint contracture
compared to a 78 % reduction seen in joints treated later (P=
0.15). A limitation of this analysis is that study duration was
not sufficient to assess if treatment of earlier-stage DC dimin-
ishes progression or recurrence.
In the double-blind phase of the CORD I/II clinical trials,
patients could receive up to three injections of CCH to achieve
clinical success. Blazer et al. retrospectively evaluated effica-
cy and safety outcomes in patients enrolled in CORD I/II who
received CCH for a contracture >5° and <20° (i.e., patients
who achieved this degree of contracture after the first injection
and subsequently received another injection); outcomes for
joints treated when contracture was >5° and <20° were com-
pared with outcomes for joints treated when contracture was
≥20° [7]. The analysis showed that clinical success rates were
higher for joints with contractures >5° and <20° (73 %, MP;
35 %, PIP) compared with contractures ≥20° (66 %, MP;
31 %, PIP). CCH may be an option to consider for less severe
contractures and allow for earlier intervention in cases where
surgical correction is delayed.
Correction of PIP contracture with CCH is associated with
lower patient satisfaction than correction of MP contracture.
In a retrospective chart review of 49 patients who received
CCH for MP and PIP contractures, Couceiro et al. showed a
significant difference in patient satisfaction related to degree
of PIP correction [11]. There was a significant (P=0.029)
difference in patient satisfaction between those with PIP con-
tractures who achieved a greater correction (mean=37.7°)
compared with those with less correction (mean=8.9°). The
difference in patient satisfaction was significant comparing
MP and PIP contractures of the small finger (P=0.00001),
indicating overall that affected joint, digit, and degree of
contracture correction have an important bearing on patient
satisfaction with CCH treatment. Couceiro et al. concluded
that postinjection manipulation of the small finger is more
difficult with PIP than MP joint contracture after CCH. Thus,
earlier intervention in PIP contractures with less contracture
and possibly less finger manipulation, particularly for the
small finger, may enable better outcomes in terms of patient
satisfaction.
Injections into multiple cords
Multiple joint contractures, whether in different hands or in
the same hand, are common in patients with DC, and treat-
ment of multiple contractures concurrently could potentially
lead to increased complications. A pilot study showed that two
cords could be concurrently treated with 0.58 mg of CCH per
cord on the same hand, with efficacy and safety comparable to
the treatment of a single cord [10]. Mean reduction in MP and
PIP contractures were 30.3° and 22.1°, and mean increase in
ROM were 30.0° and 17.1°, respectively, with no unexpected
AEs. This study only treated a small number of patients but
does suggest that two cords can be treated concurrently with
efficacy and safety comparable to single cord treatment with
CCH.
Coleman et al. reported on the results of a prospective,
open-label, phase 3b study conducted in 60 patients at 8
centers, in which 0.58 mg of CCH was injected into each of
2 palpable cords in different fingers (n=32) or same finger
(n=28) in the same hand at a single visit, followed by stan-
dardized finger extension procedure 24 h after CCH injection
and 30-day postinjection efficacy and safety follow-up [9].
After a single injection of CCH per affected joint for each of
two joints (i.e., two concurrent injections), the clinical success
rate (0°–5° contracture) was similar to that seen in the CORD
trials after a maximum of three injections [9, 21, 26]. Mean
ROM increased from 50° at baseline to 82° at day 30 postin-
jection for MP joints and 51° to 78°, respectively, for PIP
joints. Treatment-related local injection site AE rates were
comparable to the single injection AE rates in CORD I/II,
with higher rates for extremity pain, pruritus, lymphadenopa-
thy, skin laceration, and blood blister. A pulley rupture from
A2 through A4 and one tendon rupture in the right hand ring
finger were reported, with no additional complications [9].
Safety of CCH in clinical trials
Local adverse events
The overall clinical safety of CCH has been discussed at
length in a published review [2, 16], based on data from
clinical trials that included 2,630 injections in 1,780 cords in
1,082 patients with DC. Greater than 25 % of patients expe-
rienced local AEs such as edema (77 %), contusion (55 %),
injection site pain (41 %), swelling (25 %), tenderness (29 %),
and hemorrhage (35 %).
Immune-mediated reactions
Reported AEs potentially indicative of immune-mediated re-
actions include lymphadenopathy, lymph node pain, axillary
pain, erythema, peripheral edema, and injection site pruritus.
More than 85 % of patients developed anticollagenase anti-
bodies after one injection of CCH, and nearly all patients
developed antibodies after 3 injections, but with no correlation
between antibody titer and absence or presence of a possible
immune-mediated reaction or severity of such event [2, 16,
19].
Tendon rupture
In the CORD trials, three patients (0.3 %) had a flexor tendon
rupture of the treated finger within 7 days of the injection and
all three occurred after injections into the small finger [4, 16].
Hurst et al. reported that two tendon ruptures in CORD I that
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occurred in the small finger PIP joints and involved the flexor
digitorum profundus and flexor digitorum superficialis and
provided specific recommendations to reduce the potential
risk of injection into PIP joints [24, 26].
Effectiveness and safety of CCH in the practice setting
Three and a half years of experience after the introduction of
CCH has enabled a better understanding of the effectiveness
and utilization of CCH in clinical practice vs the results of
clinical trials with their more rigorous methodologies.
Variations in procedures and clinical experience in the practice
setting may influence both safety and efficacy outcomes.
Relevant factors include use of anesthesia, clinical experience
with the injection and finger extension techniques, and how
the pattern of use may be influenced by patient lifestyles and
treatment expectations.
The effectiveness of CCH in the practice setting has been
assessed by a chart review conducted at 10 US community
and academic practice sites [40]. Data were based on 501
patients (74 % male; mean age 65 years), with 92 % (463/
501) having sufficient data for analysis. The number of injec-
tions analyzed was 680 (422 MP, 258 PIP). Mean baseline
contracture was 49° overall, 44° for MP joints, and 57° for PIP
joints; mean posttreatment contracture was 12°, 8°, and 19°,
respectively; and mean posttreatment ROMwas 81°, 83°, and
77°, respectively. The practice setting showed a lower rate of
injections per joint (1.08 for chart review vs 1.7 for clinical
trials), and 93 % of joints received only one injection [40].
Local anesthesia postinjection before the finger extension
procedure was adjunctive in 86 % (363/424) of cases (65 %,
digit or metacarpal block only). The mean number of finger
extension attempts per visit was 1.3, and only 18 % (77/424)
of patients received finger extension beyond one attempt. A
full release of cord was achieved in 67 % (284/434) of cases
after the first injection (as compared to clinical success rate of
39 % in the CORD I trial after the first injection [26]) and was
higher inMP (75 %) than PIP (48 %) of joints. The higher rate
of full release after first injection in this chart review may
possibly be related to the use of anesthesia during finger
extension, less rigorous criteria for success than in the clinical
trials, or that patients were generally satisfied with less than
full extension. However, posttreatment contracture and ROM
in this chart review were similar to CORD I/II but with fewer
injections [40]. Fewer injections per joint, no requirement for
physical hand therapy, and potentially fewer visits have im-
portant implications for health care resource utilization.
Similar findings of effectiveness also were shown by
DeMarco et al. in a retrospective case series of 27 patients
treated in rheumatology clinics [14]. The patients received 47
injections of CCH (0.58 mg) into 37 cords; 78 % (21/27) of
patients met the inclusion criteria for CORD I/II. In contrast to
the CORD trials, anesthesia was used in 72 % (34/47) of
finger extension procedures, and ultrasound with high-
resolution probe was used to guide CCH injection to avoid
injury to the tendon sheath. Clinical success was achieved in
78 % (29/37) of all cords and in a higher percentage (93 %) of
27 cords that would have met CORD trial entry criteria. This
compares favorably with 64 and 44 % achieving clinical
success in the CORD I and CORD II trials, respectively.
Procedural complications were hemorrhagic bullae (2), skin
tearing (4), rash (1), lymphadenopathy (1), and axillary ec-
chymosis (1), which all resolved. As in the previous chart
review, this rheumatology practice setting also showed a
lower rate of injections per joint than the CORD trials (1.3
vs 1.7), and the higher clinical success rate might have been
attributable to use of anesthesia.
Postapproval safety surveillance
Ongoing postapproval surveillance of CCH safety is based on
the MedWatch program, where AEs are voluntarily reported
to FDA by patients and health care professionals and subse-
quently entered into FDA’s Adverse Event Reporting System
(FAERS), which is accessible online. Peimer et al. analyzed
the spontaneous reports received by the manufacturer in the
first year after approval (from February 3, 2010 through
February 2, 2011) and found that CCH’s safety profile was
similar to that previously reported in clinical trials [38]. A total
of 270 AE were reported in 115 patients, representing a drug
exposure of approximately 5,400 injections. The most com-
monly reported AEs in the 1-year follow-up were skin lacer-
ation or tear (35 events), peripheral edema (30 events), and
contusion (26 events). Most of the 35 reported skin tears
healed without skin graft (2 patients) [38]. The analysis indi-
cates lower reported rates of tendon rupture compared with
controlled data from clinical trials. Tendon rupture in clinical
trials was 1.14 per 1,000 injections [16], while the two tendon
ruptures and one pulley injury in the spontaneous report
represent a tendon rupture rate of 0.37 per 1,000 injections
and a ligament injury rate of 0.15 per 1,000 injections [38]. A
30-month follow-up of postapproval safety has been reported
for approximately 27,000 injections in 21,000 patients.
Nineteen tendon ruptures and 3 ligament injuries were report-
ed, representing a tendon rupture rate of 0.7 per 1,000 injec-
tions and a ligament injury rate of 0.11 per 1,000 injections.
Thus, tendon rupture and ligament injury occured at a lower
reported rate than in clinical trials, suggesting that the Risk
Evaluation and Mitigation Strategy (REMS) training program
has been effective. Tendon rupture following treatment of PIP
contracture in clinical trials involved the small finger, and 3-
year postapproval data showed greater risk in this digit; how-
ever, tendon rupture can occur in any finger or joint. One
reason for this is that vertical (perpendicular) injection of CCH
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into the joint can result in missing the cord and injecting the
tendon because there is limited space between cord and ten-




A systematic literature review of English and non-English
articles on DC published from September 1, 1960 until
December 1, 2010 was conducted using Medline,
EMBASE, and the Cochrane Database of Systematic
Reviews [46]. The review, which used American Society for
Surgery of the Hand (ASSH) level of evidence criteria, con-
sidered factors that influence treatment decisions, such as
number of fingers affected, type of joint, and severity of
contracture, and also reviewed type of study, how the research
question was determined, and level of evidence as a frame-
work for analysis of the DC literature [1, 54]. A decision tree
for treatment of DC was constructed based on available
evidence-based medicine for the three primary modalities,
namely, fasciectomy, needle aponeurotomy, and CCH. Sixty-
six percent (191/289) of peer-reviewed papers identified
consisted of case series or expert opinion, and only 14 papers
qualified by ASSH criteria for level 1 or level 2 evidence (8
fasciectomy, 5 CCH, 1 NP). This review revealed that as more
treatment options become available, decision-making is ham-
pered by a limited number of high-level studies and that
sufficient data from prospective, randomized, clinical trials
to guide clinicians who treat DC remains an unmet need.
Until such time, important factors that influence treatment
decisions include number/type of affected joints, severity of
contracture/rate of progression, surgical history, and patient-
centric issues.
CCH can be used to treat contractures that interfere with
hand function and cause functional disability affecting ADLs
or patient lifestyles, provided that the patient has both a
palpable cord and no comorbidities that may interfere with
treatment [23]. In the CORD trials, patients had a palpable
Dupuytren’s cord and at least 20° of MP or PIP contracture
and were not able to simultaneously place the affected finger
and palm flat on a table. MP contractures ≥30° and PIP
contractures ≥20° usually result in a positive table-top
test and interfere with hand function [23]. An addition-
al consideration for utilization of CCH is a web con-
tracture that interferes with grasp or pinch. There is no
contraindication to the use of CCH, but comorbidities to
consider include coagulation disorders, use of anticoag-
ulant, or chronic muscular, neurologic, or neuromuscular
disorders affecting the hand.
Injection technique
The CCH injection technique was modified based on experi-
ence in the CORD I trial. It is recommended that the injection
should be made with a 27-gauge, 1.25-mm (0.5 in.) needle.
Cords of the little finger should be injected nomore than 4mm
distal to the palmar crease and no deeper than 2 to 3 mm [26].
In addition, the needle should be placed into the PIP cord on a
horizontal plane and not vertically. Stabilizing the needle
while pushing the plunger also helps to prevent injection
through the cord [24].
A REMS is a strategy designed to manage a known or
potential serious risk associated with a drug or biological
product. The REMS for CCH was developed to inform health
care providers about the risks of tendon rupture, serious AEs
affecting the injected extremity, and the potential risk of
serious hypersensitivity reactions (including anaphylaxis) as-
sociated with CCH [3]. The REMS communication plan
includes a training guide and video for health care providers
who are likely to prescribe CCH, including hand surgeons,
orthopedic surgeons, plastic surgeons, general surgeons, and
rheumatologists. REMS provides clinicians with instructions
for properly preparing and injecting CCH and using the proper
finger extension procedure to achieve cord disruption.
Enrollment consists of three steps: (1) reviewing the training
materials; (2) completing, signing, and faxing the physician
enrollment form to be able to order CCH; and (3) completing,
signing, and faxing the site enrollment form to register site(s)
for shipping.
Finger extension technique
Skin lacerations are common and treatment-related lacerations
occurred at a rate of 11% in the clinical trials [16]. Risk of skin
tears is greater as severity of contracture increases, and these
lacerations occurred primarily in patients who had experi-
enced severe baseline contracture over many years [27]. The
cord can become adherent to the skin overlying the cord,
which often becomes thin and more easily damaged [19].
Thus, over-strenuous postinjection manipulation should be
avoided to reduce the risk of skin laceration, which can also
interfere with fitting a good splint because of pain. In the
clinical trials, skin lacerations healed without treatment and
did not affect clinical outcome. In the published 1-year
postapproval surveillance review, skin tear was reported at a
rate of 6.5 per 1,000 injections [38].
Adherence to the recommended CCH postinjection stan-
dardized manipulation procedure is advised to reduce the risk
of skin tear, especially in more advanced disease. The proce-
dure for finger manipulation is also discussed in the REMS for
CCH. Practitioner experience over time helps to reduce the
incidence of skin tears, and follow-up care is very important in
achieving the desired outcomes. Patients should be instructed
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to perform daily finger extension and flexion exercises during
recovery and not to perform strenuous activity with the
injected hand along with the proper, compliant use of night-
time splint.
Spontaneous cord rupture
Spontaneous cord rupture has occurred after CCH injection.
Gill et al. retrospectively reviewed 36 consecutive patients
(43 joints) treated with a standard injection of CCH, follow-
ed by a 24-h return visit [20]. Average baseline MP and PIP
contractures were 43.1° and 53.5°, respectively. Twenty-
nine joints achieved full correction (20 MP, 9 PIP), and 7
patients had spontaneous cord rupture, resulting in full (4
patients) or partial correction (3 patients). Skin tear occurred
in 3 of 36 patients. A recent MRI examination of cord
structure in five patients who were treated with CCH and
had no residual contracture after finger manipulation
showed that CCH does not simply weaken the cord but
actually causes disorganization and dissolution of the cord,
which may help to explain the histologic basis for sponta-
neous cord rupture. MRI demonstrated discontinuity of the
cord in all cases along with a significant reduction in cord
volume from 670 to 188 mm3 and a significant increase in
signal intensity (demonstrating disorganization of cord col-
lagen) from 632 to 2,021, an average of 320 %, which
together showed both significant reductions in diseased
tissue rather than simple cord division and significant dis-
organization of cord collagen [35].
Splinting after CCH
Following the finger extension procedure(s), patients should
be fitted with a splint and provided instructions for use at
bedtime for up to 4 months to maintain finger extension [3].
A recent study by Skirven et al. showed that treatment with
CCH followed by gradual and progressive extension of the
joint using a splint may be a more effective intervention
strategy than passive extension used in the trials [45].
Twenty-one patients (22 fingers) with a mean passive PIP
joint contracture of 56° received one injection of CCH.
Contracture was reduced to 22° at time of cord rupture,
followed by further decreases in PIP contracture to a mean
of 12° 1 week later. Only 22 to 25 % of PIP joints in the
CORD trial achieved clinical success compared with 55 % of
joints in this study. Although local anesthesia (lidocaine) was
not mandated by protocol in the CORD trials, it was used in
this study andmay have contributed to better results compared
with the CORD trials. The use of anesthesia was particularly
effective during cord rupture because it allowed patients to
better tolerate the postinjection manipulation and led to fewer
injections.
Reimbursement
Because insurance coverage varies by payor and patient,
health care providers should verify each patient’s health care
benefits prior to initiating treatment. Individual plans may
require a preauthorization evaluation. The general criteria
include a letter of medical necessity, completion of a payor-
specific prior authorization form, appropriate chart notes,
history of past therapy and result, and a product information
package insert. Medicare Part B patients do not require a
preauthorization. Additionally, financial assistance may be
available through the manufacturer for those patients who
qualify.
Cost-effectiveness
Health care decisions are based not only on efficacy and safety
but also on economic considerations. Since the introduction of
CCH, postapproval studies have been conducted to evaluate
the cost-effectiveness of CCH. Malone and Armstrong used a
Markov decision model to determine the comparative cost-
effectiveness of CCH, limited fasciectomy (LF), and percuta-
neous needle fasciotomy (PNF) [33]. The study perspective
was from that of a US payer. Patients were classified in the
analysis based on clinical success after treatment, treatment
failure resulting in revision, disease progression, and death.
CCH was less expensive and associated with slightly more
quality-adjusted life years (QALYs) than LF or PNF.
Estimated mean costs over a 30-year period were US$4,489,
US$18,345, and US$14,970 for CCH, LF, and PNF,
respectively.
Ines et al. conducted a cost minimization study to estimate
the cost of CCH versus fasciectomy in Portuguese patients
with DC [28]. The direct costs and inpatient cost of surgery as
well as postsurgical costs associated with patient follow-up
visits and physiotherapy were estimated. The direct cost of
CCH included vials used, administration of injection in an
outpatient setting, and outpatient follow-up visits. The prima-
ry determinates of direct cost favoring CCH over surgery were
reduction in cost of inpatient services and postsurgical phys-
iotherapy, and the indirect cost favoring CCH was loss of
productivity due to time out of work. The overall savings of
CCH over surgery was 1,674€. There was a slight advantage
related to direct costs, but the main advantage was related to
the indirect cost of productivity loss.
Productivity loss has been studied by Naam in a recently
published retrospective, longitudinal study of at least 2 years
duration that compared CCH (n=25) with fasciectomy (n=
21) [36]. Postprocedural follow-up averaged 32 months for
CCH and 39 months for fasciectomy. Mean CCH postinjec-
tion contracture was 3.6° and 17.5° for MP and PIP joints,
respectively, compared with 3.7° and 8.1° for fasciectomy,
respectively. Patients treated with CCH returned to work at a
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mean of 1.9 days compared with 37.4 days after fasciectomy.
There was no difference between groups related to type of
work, no patient in the study met the criteria for recurrence
(≥20° from time of joint correction), and no serious AEs were
reported for either intervention.
Sau et al. conducted a cost-effectiveness study of CCH, LF,
and PNF using a Markov model [43]. Of the three treatment
interventions, the analysis favored LF, with CCH and PNF
costing an average of US$1,844 and US$247 more than LF,
respectively. The model is sensitive to cost of surgery, which
may have variable outcomes related to postsurgical complica-
tions and associated costs. LF is the most frequently used
procedure by hand surgeons in the USA, but a drawback of
this procedure is a cumulative complication rate estimated to
be as high as 19 % [50]. In addition, it is unclear whether
recurrence was included in this model, a reported disadvan-
tage of PNF, with an estimated recurrence rate as high as 85%
over 5 years [51].
An assessment of the direct and indirect costs of employees
with DC compared with a matched cohort of non-DC em-
ployees showed that employees with DC had higher comor-
bidity rates, health care utilization, and work loss than non-DC
employees. These factors resulted in increased mean health
care costs of approximately US$4,227 for DC vs non-DC
patients over a 9-year survey period [32], suggesting that the
cost savings of early intervention should be weighed against
the costs associated with prolonged, progressive DD.
De Salas-Cansado et al. conducted an analysis in Spanish
patients to estimate the budget impact of CCH versus
fasciectomy [13]. The analysis showed a difference in cost
favoring CCH over fasciectomy for a typical case to be 1,030
€, with a substantial difference in 3-year overall base-case
budgetary impact of 8,835,750€ for fasciectomy and
3,819,591€ for CCH, suggesting that CCH can result in a
substantial savings as a noninvasive outpatient procedure.
Conclusions
CCH is a minimally invasive technique for treating
Dupuytren’s contracture caused by collagen cords. It can be
done in an office setting and is associated with mostly local
AEs and short healing times compared with surgery. Clinical
trials have shown that CCH is both effective and well tolerated
and like surgery produces better responses in patients with less
severely contracted joints. Postapproval surveillance has
shown a safety profile similar to that seen in clinical trials
and effectiveness equivalent to or better than that seen in
clinical trials. A standardized finger extension procedure that
includes local anesthesia helps reduce patient discomfort, and
risks associated with CCH injection such as tendon rupture
can be reduced through the use of the proper injection
technique, a standardized finger extension procedure, and
the REMS program developed to help physicians administer
CCH safely.
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